Nurix Therapeutics (NRIX) Cash from Investing Activities (2019 - 2026)
Nurix Therapeutics (NRIX) posted quarterly Cash from Investing Activities of $93.0 million for Q2 2026, up 30.07% year-over-year from $71.5 million in Q2 2025, and up 175.1% quarter-over-quarter from -$123.8 million in Q1 2026.
Powered by 
Analysis
Nurix Therapeutics (NRIX) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has reported Cash from Investing Activities for 8 consecutive years, with $93.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 30.07% year-over-year to $93.0 million; the TTM figure through May 2026 stood at $20.0 million (up 130.7% YoY), while the FY2025 annual figure was $147.9 million, up 157.37% from the prior year.
- Cash from Investing Activities climbed to $93.0 million in Q2 2026 per NRIX's latest filing, from -$123.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $93.0 million in Q2 2026 and bottomed at -$140.8 million in Q4 2024.
- Historically, Cash from Investing Activities has averaged -$2.5 million across 5 years, with a median of $19.4 million in 2023.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 1777.04% — and 2024, when it slumped 879.73%.
- Nurix Therapeutics' Cash from Investing Activities stood at $55.0 million in 2022, then sank by 126.13% to -$14.4 million in 2023, then plunged by 879.73% to -$140.8 million in 2024, then surged by 100.25% to $346000.0 in 2025, then soared by 26777.75% to $93.0 million in 2026.
- Business Quant data shows NRIX's Cash from Investing Activities at $93.0 million in Q2 2026, -$123.8 million in Q1 2026, and $346000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - | 93.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | 93.00 Mn |
| Feb 28, 2026 | -123.83 Mn |
| Nov 30, 2025 | 346,000.00 |
| Aug 31, 2025 | 50.48 Mn |
| May 31, 2025 | 71.50 Mn |
| Feb 28, 2025 | 25.53 Mn |
| Nov 30, 2024 | -140.82 Mn |
| Aug 31, 2024 | -21.34 Mn |
| May 31, 2024 | -131.07 Mn |
| Feb 29, 2024 | 35.51 Mn |
| Nov 30, 2023 | -14.37 Mn |
| Aug 31, 2023 | 22.78 Mn |
| May 31, 2023 | 43.83 Mn |
| Feb 28, 2023 | 16.07 Mn |
| Nov 30, 2022 | 55.01 Mn |
| Aug 31, 2022 | -63.08 Mn |
| May 31, 2022 | -4.77 Mn |
| Feb 28, 2022 | 40.03 Mn |
| Nov 30, 2021 | -36.52 Mn |
| Aug 31, 2021 | -12.23 Mn |